{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670320290960128.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1023/a:1008206519571"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0923753419558148?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0923753419558148?httpAccept=text/plain"}},{"identifier":{"@type":"URI","@value":"http://academic.oup.com/annonc/article-pdf/9/4/385/19481750/9-4-385.pdf"}}],"dc:title":[{"@value":"Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin’s lymphoma"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380567003960719109","@type":"Researcher","foaf:name":[{"@value":"F.L. Clark"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320290960130","@type":"Researcher","foaf:name":[{"@value":"M.W. Drummond"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320290960132","@type":"Researcher","foaf:name":[{"@value":"S. Chambers"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320290960129","@type":"Researcher","foaf:name":[{"@value":"B.A. Chapman"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320290960131","@type":"Researcher","foaf:name":[{"@value":"W.N. Patton"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09237534"}],"prism:publicationName":[{"@value":"Annals of Oncology"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"1998-04","prism:volume":"9","prism:number":"4","prism:startingPage":"385","prism:endingPage":"387"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","http://www.elsevier.com/open-access/userlicense/1.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0923753419558148?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0923753419558148?httpAccept=text/plain"},{"@id":"http://academic.oup.com/annonc/article-pdf/9/4/385/19481750/9-4-385.pdf"}],"createdAt":"2002-12-22","modifiedAt":"2024-12-07","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1390282679767056896","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case of autoimmune hepatitis with hepatitis B carrier was safely performed corticosteroid therapy by prophylaxis of lamivudine"},{"@language":"ja","@value":"ＨＢＶ持続感染に対してラミブジンを併用してステロイド治療を施行した自己免疫性肝炎の１例"},{"@value":"症例報告 HBV持続感染に対してラミブジンを併用してステロイド治療を施行した自己免疫性肝炎の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク HBV ジゾク カンセン ニ タイシテ ラミブジン オ ヘイヨウ シテ ステロイド チリョウ オ シコウ シタ ジコ メンエキセイ カンエン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/2050870367073795072","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1023/a:1008206519571"},{"@type":"CROSSREF","@value":"10.1007/s10157-011-0464-7_references_DOI_2wY8i206eljEeWbjFBJZqNEpZgI"},{"@type":"CROSSREF","@value":"10.2957/kanzo.46.557_references_DOI_2wY8i206eljEeWbjFBJZqNEpZgI"}]}